RE: Nteresting how much focus is shifting from AIM noise to Phase 3/Fast Track potential now — feels like the market is finally starting to price in the scale of the opportunity26 May 2026 13:09
I cannot say who is right or wrong in this debate but EE does raise a valid point in so much as a number of MHRA board members have ties to global pharmaceutical companies. However there are formal procedures to follow when dissatisfied with the service provided by MHRA ie. mistakes, unreasonable and/or unexplained delays etc. With that in mind, I’d put some faith in Scancell’s leadership and that if they believed a formal complaint needed to be made and also escalated to MHRA, they would already have done that.
IMO